Efficacy of a Microalgae Extract PhaeoSOL Combined With Natural Stimulant on Cognitive Function and Gaming Performance of Video Gamers
NCT ID: NCT04851899
Last Updated: 2022-09-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2021-04-26
2022-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Thus, the purpose of this study is to examine whether acute (single-dose) and chronic (1 month) supplementation of Microphyt's phaeosol ingredients (BrainPhyt) ingested with or without a natural stimulant, would affect cognitive function and gaming performance in experienced video gamers.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nutrition21 Study 1
NCT04828278
Nutritional Supplement's Effects on Cognition
NCT05941949
Impact of AMATEA™️ on Physiological Measures and Gaming Performance in Active Gamers: a Placebo Controlled, Double-blind, Randomized Study
NCT04234529
Impact of Astaxanthin on Cognition in Recreationally Active Females
NCT06460181
The Effect of α-GPC on Cognitive Function and Sports Performance
NCT07267845
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low dose Phaeosol group
1 Phaeosol softgel of 440mg/day and 1 placebo softgel of 440mg/day look like softgel of Phaeosol product) + 1 capsule of 440mg/day of natural stimulant
Phaeosol low dose
1 Phaeosol softgel of 440mg/day and 1 placebo softgel of 500mg/day (look like softgel of Phaeosol product) + 1 capsule of 440mg/day of natural stimulant Subjects were instructed to take the study supplement or placebo once daily for 1 months (±2 days). The first and the last doses will be administered at the clinical site during Visit 2 (Experiment 1) and Visit 3 (Experiment 2, respectively).
High dose Phaeosol group
2 Phaeosol softgels of 440mg/day + 1 capsule of 440mg/day of natural stimulant
Phaeosol high dose
2 Phaeosol softgels of 440mg/day + 1 capsule of 440mg/day of natural stimulant. Subjects were instructed to take the study supplement or placebo once daily for 1 months (±2 days). The first and the last doses will be administered at the clinical site during Visit 2 (Experiment 1) and Visit 3 (Experiment 2, respectively).
Placebo group
2 placebo softgels of 440mg/day (look like softgel of Phaeosol product) + 1 capsule of 440mg/day containing Microcellulose (look like capsule of natural stimulant)
Placebo
2 placebo softgels of 440mg/day (look like softgel of Phaeosol product) + 1 capsule of 500mg/day containing Microcellulose (look like capsule of natural stimulant). Subjects were instructed to take the study supplement or placebo once daily for 1 months (±2 days). The first and the last doses will be administered at the clinical site during Visit 2 (Experiment 1) and Visit 3 (Experiment 2, respectively).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Phaeosol low dose
1 Phaeosol softgel of 440mg/day and 1 placebo softgel of 500mg/day (look like softgel of Phaeosol product) + 1 capsule of 440mg/day of natural stimulant Subjects were instructed to take the study supplement or placebo once daily for 1 months (±2 days). The first and the last doses will be administered at the clinical site during Visit 2 (Experiment 1) and Visit 3 (Experiment 2, respectively).
Phaeosol high dose
2 Phaeosol softgels of 440mg/day + 1 capsule of 440mg/day of natural stimulant. Subjects were instructed to take the study supplement or placebo once daily for 1 months (±2 days). The first and the last doses will be administered at the clinical site during Visit 2 (Experiment 1) and Visit 3 (Experiment 2, respectively).
Placebo
2 placebo softgels of 440mg/day (look like softgel of Phaeosol product) + 1 capsule of 500mg/day containing Microcellulose (look like capsule of natural stimulant). Subjects were instructed to take the study supplement or placebo once daily for 1 months (±2 days). The first and the last doses will be administered at the clinical site during Visit 2 (Experiment 1) and Visit 3 (Experiment 2, respectively).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Between 18 and 40 years;
3. Self-reported history of playing video games for 5 or more hours per week for 6 months prior to screening;
4. BMI between 18 and 34.9 Kg/m2 ;
5. Subjects agreed to supply their own operator-oriented action or strategy video game that they had played at least 21 times over the last 3 months;
6. No recent ingestion (\<2weeks) of dietary supplement that affect cognitive function;
7. Be able to give written informed consent and to consume the investigational product daily for the duration of the study;
8. Is free-living (living in a private home, alone or with family, and able to maintain their health and hygiene without assistance)
9. Willing to maintain consistent sleep duration the evening before study visits.
10. Are agreed to continue their patterned use of the game between study visits
Exclusion Criteria
2. consume dietary supplements that may affect cognition and/or with a stimulant effect (e.g. guarana, cocoa, ginseng, bacopa, Gingko biloba, guayusa, yerba mate, energy drinks, other products containing fucoxanthin) at least 7 days before Visit 2 ;
3. are women who are pregnant, breastfeeding, or wish to become pregnant during the study;
4. have an untreated psychotic or major depressive disorder or any history of cognitive deficit;
5. have an uncontrolled hypertension/diabetes/thyroid/heart disease disease, cancer etc.);
6. have a significant neurological disease;
7. have planned major changes in lifestyle (i.e. diet, dieting, exercise level, travelling) during the duration of the study;
8. have a history within previous 12 months of alcohol or substance abuse;
9. have known allergy to any of the ingredients in the supplement product
10. are not willing to supply their own gaming system and/or game
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Texas A&M University
OTHER
Microphyt
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Richard Kreider, Professor
Role: PRINCIPAL_INVESTIGATOR
Texas A&M University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Exercise & Sport Nutrition Lab
College Station, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Leonard M, Maury J, Dickerson B, Gonzalez DE, Kendra J, Jenkins V, Nottingham K, Yoo C, Xing D, Ko J, Pradelles R, Faries M, Kephart W, Sowinski R, Rasmussen CJ, Kreider RB. Effects of Dietary Supplementation of a Microalgae Extract Containing Fucoxanthin Combined with Guarana on Cognitive Function and Gaming Performance. Nutrients. 2023 Apr 15;15(8):1918. doi: 10.3390/nu15081918.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB2021-0219
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.